Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed drug combination for the management of type 2 diabetes.
According to an official statement, the company launched a fixed-dose combination (FDC) of its novel, patent-protected, globally researched Sodium-Glucose Co-Transporter Inhibitor (SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin (first-line medication for the treatment of type 2 diabetes).
“The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed-dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo MV and Remozen MV,” the company said in a statement.
With the launch of Remogliflozin-Vildagliptin-Metformin fixed-dose combination (FDC), Glenmark has become the first company in the world to do so and India becomes the first country to gain access to this FDC drug.
“Glenmark received approval from the DCGI (the drug approval authority in India) for manufacturing and marketing this fixed-dose combination in late September 2021,” said the statement. It’s FDC of Remogliflozin-Vildagliptin-Metformin tackles most of the pathophysiology in type 2 diabetes that makes it an appealing fixed-dose combination in managing uncontrolled type 2 diabetes.
The company said that the cost of the drug will be Rs 16.50 per tablet, to be taken twice daily as against Rs 75 as an average cost of existing brands.
